MedTrace Logo

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

NCT00502567 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2011-07-27

No results posted yet for this study

Summary

A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

AZD2171

oral tablet once daily

DRUG

FOLFOX

intravenous infusion

DRUG

Pemetrexed

intravenous infusion

DRUG

Irinotecan (administered with & without Cetuximab)

intravenous injection

DRUG

Docetaxel

intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Jane Robertson · AstraZeneca

  • Bijoyesh Mookerjee, MD · AstraZeneca

  • Patricia LoRusso, DO · Wayne State University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-11-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502567 on ClinicalTrials.gov